Cargando…

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

INTRODUCTION: In contrast to nonsteroidal aromatase inhibitors, the steroidal aromatase inactivator exemestane does not have detrimental effects on bone in animal models. This study was designed to compare the effects of exemestane with the nonsteroidal aromatase inhibitors anastrozole and letrozole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goss, Paul E, Hadji, Peyman, Subar, Milayna, Abreu, Paula, Thomsen, Torben, Banke-Bochita, Jose
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206728/ https://www.ncbi.nlm.nih.gov/pubmed/17692126 http://dx.doi.org/10.1186/bcr1757

Ejemplares similares

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Impact of nonsteroidal aromatase inhibitors on steroid profile in a Chinese population
por: Xing, Yanyi, et al.
Publicado: (2017)

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
por: Wang, Xue, et al.
Publicado: (2020)

Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study
por: Bryce, Jane, et al.
Publicado: (2012)

CORRIGENDUM to “Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study”
Publicado: (2020)

The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs
por: Gao, Lanyang, et al.
Publicado: (2019)

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer
por: Freedman, OC, et al.
Publicado: (2009)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
por: Lee, June Koo, et al.
Publicado: (2013)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer
por: Pfeiler, G, et al.
Publicado: (2013)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Influence of Obesity on Bone Turnover Markers and Fracture Risk in Postmenopausal Women
por: López-Gómez, Juan J., et al.
Publicado: (2022)

Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study
por: Ziller, Volker, et al.
Publicado: (2013)

Relationship between Serum Total Cholesterol Level and Serum Biochemical Bone Turnover Markers in Healthy Pre- and Postmenopausal Women
por: Jeong, Tae-Dong, et al.
Publicado: (2014)

Establishing Reference Intervals for Bone Turnover Markers in the Healthy Shanghai Population and the Relationship with Bone Mineral Density in Postmenopausal Women
por: Hu, Wei-Wei, et al.
Publicado: (2013)

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
por: Shiraki, M., et al.
Publicado: (2012)

Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism
por: Adolf, Christian, et al.
Publicado: (2020)

Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
por: Shioi, Yoshihiro, et al.
Publicado: (2014)

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Organizing Effects of Sex Steroids on Brain Aromatase Activity in Quail
por: Cornil, Charlotte A., et al.
Publicado: (2011)

Kinetic of bone turnover markers after osteoporotic vertebral compression fractures in postmenopausal female
por: Pan, Changyu, et al.
Publicado: (2018)

Correction: Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism
por: Adolf, Christian, et al.
Publicado: (2021)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women
por: Kharroubi, Akram, et al.
Publicado: (2017)

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis
por: Mederle, Ovidiu Alexandru, et al.
Publicado: (2018)

Exploring the Relationship of Bone Turnover Markers and Bone Mineral Density in Community-Dwelling Postmenopausal Women
por: Wei, Xu, et al.
Publicado: (2021)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane
por: Luo, Shaman, et al.
Publicado: (2018)

19-hydroxy Steroids in the Aromatase Reaction: Review on Expression and Potential Functions
por: Abaffy, Tatjana, et al.
Publicado: (2021)

Morphological and Functional Changes in Skin of Adult Male Rats Chronically Treated with Letrozole, a Nonsteroidal Inhibitor of Cytochrome P450 Aromatase
por: Misiakiewicz-Has, Kamila, et al.
Publicado: (2020)

Traditional Nonsteroidal Anti-Inflammatory Drugs and Postmenopausal Hormone Therapy: A Drug–Drug Interaction?
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2007)

Use of steroid and nonsteroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review protocol
por: Del Grossi Moura, Mariana, et al.
Publicado: (2018)

Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists
por: Marzolla, V., et al.
Publicado: (2021)

Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer – a retrospective cohort study
por: Stumpf, Ulla, et al.
Publicado: (2020)

Reference Intervals for Bone Turnover Markers in Korean Healthy Women
por: Cho, Dong Hyeok, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q1hvcifn0qp341mskp5am8vg2s